Showing results (221-230 of 286) with videos related to

Sort By:
Pageof 29
BMC Cancer|December 14, 2018
Management of uterine sarcomas and prognostic indicators: real world data from a single-institutionAnastasios Kyriazoglou, Michael Liontos, Dimitrios C Ziogas, et al.
Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.
Anti-Cancer Drugs|February 2, 2023
Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigmAristotelis Bamias, Roubini Zakopoulou, Kimon Tzannis, et al.
Neurology|May 1, 2019
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathyHanns Lochmüller, Anthony Behin, Yoseph Caraco, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
<i>BRCA1/2</i> Mutation Types Do Not Affect Prognosis in Ovarian Cancer PatientsMichalis Liontos, Eleni Zografos, Panagiotis Zoumpourlis, et al.
Vaccines|September 23, 2022
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted AgentsFlora Zagouri, Alkistis Papatheodoridi, Michalis Liontos, et al.
Cancers|June 10, 2022
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint InhibitionEvangelos Terpos, Michalis Liontos, Oraianthi Fiste, et al.
Breast (Edinburgh, Scotland)|September 4, 2021
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitorsFlora Zagouri, Evangelos Terpos, Oraianthi Fiste, et al.
Vaccines|October 26, 2021
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP InhibitorsMichalis Liontos, Evangelos Terpos, Christos Markellos, et al.
Prostate Cancer and Prostatic Diseases|October 10, 2021
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patientsMichalis Liontos, Evangelos Terpos, Elena Kunadis, et al.
Pageof 29